298 related articles for article (PubMed ID: 16605302)
21. Exposure Route Influences Disease Severity in the COVID-19 Cynomolgus Macaque Model.
Bixler SL; Stefan CP; Jay AN; Rossi FD; Ricks KM; Shoemaker CJ; Moreau AM; Zeng X; Hooper JW; Dyer DN; Frick OM; Koehler JW; Kearney BJ; DiPinto N; Liu J; Tostenson SD; Clements TL; Smith JM; Johnson JA; Berrier KL; Esham HL; Delp KL; Coyne SR; Bloomfield HA; Kuehnert PA; Akers K; Gibson KM; Minogue TD; Nalca A; Pitt MLM
Viruses; 2022 May; 14(5):. PubMed ID: 35632755
[TBL] [Abstract][Full Text] [Related]
22. Intranasal vaccination of recombinant adeno-associated virus encoding receptor-binding domain of severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein induces strong mucosal immune responses and provides long-term protection against SARS-CoV infection.
Du L; Zhao G; Lin Y; Sui H; Chan C; Ma S; He Y; Jiang S; Wu C; Yuen KY; Jin DY; Zhou Y; Zheng BJ
J Immunol; 2008 Jan; 180(2):948-56. PubMed ID: 18178835
[TBL] [Abstract][Full Text] [Related]
23. Functional genomics highlights differential induction of antiviral pathways in the lungs of SARS-CoV-infected macaques.
de Lang A; Baas T; Teal T; Leijten LM; Rain B; Osterhaus AD; Haagmans BL; Katze MG
PLoS Pathog; 2007 Aug; 3(8):e112. PubMed ID: 17696609
[TBL] [Abstract][Full Text] [Related]
24. Complete protection against severe acute respiratory syndrome coronavirus-mediated lethal respiratory disease in aged mice by immunization with a mouse-adapted virus lacking E protein.
Fett C; DeDiego ML; Regla-Nava JA; Enjuanes L; Perlman S
J Virol; 2013 Jun; 87(12):6551-9. PubMed ID: 23576515
[TBL] [Abstract][Full Text] [Related]
25. Molecular targets for diagnostics and therapeutics of severe acute respiratory syndrome (SARS-CoV).
Suresh MR; Bhatnagar PK; Das D
J Pharm Pharm Sci; 2008 Apr; 11(2):1s-13s. PubMed ID: 19203466
[TBL] [Abstract][Full Text] [Related]
26. Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins.
Wang SF; Tseng SP; Yen CH; Yang JY; Tsao CH; Shen CW; Chen KH; Liu FT; Liu WT; Chen YM; Huang JC
Biochem Biophys Res Commun; 2014 Aug; 451(2):208-14. PubMed ID: 25073113
[TBL] [Abstract][Full Text] [Related]
27. Severe acute respiratory syndrome coronavirus infection of mice transgenic for the human Angiotensin-converting enzyme 2 virus receptor.
Tseng CT; Huang C; Newman P; Wang N; Narayanan K; Watts DM; Makino S; Packard MM; Zaki SR; Chan TS; Peters CJ
J Virol; 2007 Feb; 81(3):1162-73. PubMed ID: 17108019
[TBL] [Abstract][Full Text] [Related]
28. Severe acute respiratory syndrome vaccine efficacy in ferrets: whole killed virus and adenovirus-vectored vaccines.
See RH; Petric M; Lawrence DJ; Mok CPY; Rowe T; Zitzow LA; Karunakaran KP; Voss TG; Brunham RC; Gauldie J; Finlay BB; Roper RL
J Gen Virol; 2008 Sep; 89(Pt 9):2136-2146. PubMed ID: 18753223
[TBL] [Abstract][Full Text] [Related]
29. SARS-CoV replication and pathogenesis in an in vitro model of the human conducting airway epithelium.
Sims AC; Burkett SE; Yount B; Pickles RJ
Virus Res; 2008 Apr; 133(1):33-44. PubMed ID: 17451829
[TBL] [Abstract][Full Text] [Related]
30. Aetiology: Koch's postulates fulfilled for SARS virus.
Fouchier RA; Kuiken T; Schutten M; van Amerongen G; van Doornum GJ; van den Hoogen BG; Peiris M; Lim W; Stöhr K; Osterhaus AD
Nature; 2003 May; 423(6937):240. PubMed ID: 12748632
[TBL] [Abstract][Full Text] [Related]
31. S protein of severe acute respiratory syndrome-associated coronavirus mediates entry into hepatoma cell lines and is targeted by neutralizing antibodies in infected patients.
Hofmann H; Hattermann K; Marzi A; Gramberg T; Geier M; Krumbiegel M; Kuate S; Uberla K; Niedrig M; Pöhlmann S
J Virol; 2004 Jun; 78(12):6134-42. PubMed ID: 15163706
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of severe acute respiratory syndrome coronavirus replication in a lethal SARS-CoV BALB/c mouse model by stinging nettle lectin, Urtica dioica agglutinin.
Kumaki Y; Wandersee MK; Smith AJ; Zhou Y; Simmons G; Nelson NM; Bailey KW; Vest ZG; Li JK; Chan PK; Smee DF; Barnard DL
Antiviral Res; 2011 Apr; 90(1):22-32. PubMed ID: 21338626
[TBL] [Abstract][Full Text] [Related]
33. Immunogenicity and protective efficacy in monkeys of purified inactivated Vero-cell SARS vaccine.
Qin E; Shi H; Tang L; Wang C; Chang G; Ding Z; Zhao K; Wang J; Chen Z; Yu M; Si B; Liu J; Wu D; Cheng X; Yang B; Peng W; Meng Q; Liu B; Han W; Yin X; Duan H; Zhan D; Tian L; Li S; Wu J; Tan G; Li Y; Li Y; Liu Y; Liu H; Lv F; Zhang Y; Kong X; Fan B; Jiang T; Xu S; Wang X; Li C; Wu X; Deng Y; Zhao M; Zhu Q
Vaccine; 2006 Feb; 24(7):1028-34. PubMed ID: 16388880
[TBL] [Abstract][Full Text] [Related]
34. Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus.
See RH; Zakhartchouk AN; Petric M; Lawrence DJ; Mok CPY; Hogan RJ; Rowe T; Zitzow LA; Karunakaran KP; Hitt MM; Graham FL; Prevec L; Mahony JB; Sharon C; Auperin TC; Rini JM; Tingle AJ; Scheifele DW; Skowronski DM; Patrick DM; Voss TG; Babiuk LA; Gauldie J; Roper RL; Brunham RC; Finlay BB
J Gen Virol; 2006 Mar; 87(Pt 3):641-650. PubMed ID: 16476986
[TBL] [Abstract][Full Text] [Related]
35. Prior immunization with severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) nucleocapsid protein causes severe pneumonia in mice infected with SARS-CoV.
Yasui F; Kai C; Kitabatake M; Inoue S; Yoneda M; Yokochi S; Kase R; Sekiguchi S; Morita K; Hishima T; Suzuki H; Karamatsu K; Yasutomi Y; Shida H; Kidokoro M; Mizuno K; Matsushima K; Kohara M
J Immunol; 2008 Nov; 181(9):6337-48. PubMed ID: 18941225
[TBL] [Abstract][Full Text] [Related]
36. Neutralizing antibody against severe acute respiratory syndrome (SARS)-coronavirus spike is highly effective for the protection of mice in the murine SARS model.
Ishii K; Hasegawa H; Nagata N; Ami Y; Fukushi S; Taguchi F; Tsunetsugu-Yokota Y
Microbiol Immunol; 2009 Feb; 53(2):75-82. PubMed ID: 19291090
[TBL] [Abstract][Full Text] [Related]
37. The SARS-CoV ferret model in an infection-challenge study.
Chu YK; Ali GD; Jia F; Li Q; Kelvin D; Couch RC; Harrod KS; Hutt JA; Cameron C; Weiss SR; Jonsson CB
Virology; 2008 Apr; 374(1):151-63. PubMed ID: 18234270
[TBL] [Abstract][Full Text] [Related]
38. Differences and similarities between SARS-CoV and SARS-CoV-2: spike receptor-binding domain recognition and host cell infection with support of cellular serine proteases.
Rossi GA; Sacco O; Mancino E; Cristiani L; Midulla F
Infection; 2020 Oct; 48(5):665-669. PubMed ID: 32737833
[TBL] [Abstract][Full Text] [Related]
39. Fully human monoclonal antibody directed to proteolytic cleavage site in severe acute respiratory syndrome (SARS) coronavirus S protein neutralizes the virus in a rhesus macaque SARS model.
Miyoshi-Akiyama T; Ishida I; Fukushi M; Yamaguchi K; Matsuoka Y; Ishihara T; Tsukahara M; Hatakeyama S; Itoh N; Morisawa A; Yoshinaka Y; Yamamoto N; Lianfeng Z; Chuan Q; Kirikae T; Sasazuki T
J Infect Dis; 2011 Jun; 203(11):1574-81. PubMed ID: 21592986
[TBL] [Abstract][Full Text] [Related]
40. Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants.
ter Meulen J; van den Brink EN; Poon LL; Marissen WE; Leung CS; Cox F; Cheung CY; Bakker AQ; Bogaards JA; van Deventer E; Preiser W; Doerr HW; Chow VT; de Kruif J; Peiris JS; Goudsmit J
PLoS Med; 2006 Jul; 3(7):e237. PubMed ID: 16796401
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
